Biomarin Pharmaceutical Inc
NASDAQ:BMRN
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
61.93
99
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Biomarin Pharmaceutical Inc
Operating Margin
Biomarin Pharmaceutical Inc
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | US |
| Market Cap | 12.3B USD |
| Operating Margin |
15%
|
| Country | FR |
| Market Cap | 6T USD |
| Operating Margin |
-17 527%
|
| Country | US |
| Market Cap | 320.1B USD |
| Operating Margin |
28%
|
| Country | US |
| Market Cap | 147.4B USD |
| Operating Margin |
19%
|
| Country | US |
| Market Cap | 119.4B USD |
| Operating Margin |
40%
|
| Country | US |
| Market Cap | 113.8B USD |
| Operating Margin |
38%
|
| Country | US |
| Market Cap | 94.1B EUR |
| Operating Margin |
-370%
|
| Country | AU |
| Market Cap | 135.4B AUD |
| Operating Margin |
26%
|
| Country | US |
| Market Cap | 82.6B USD |
| Operating Margin |
30%
|
| Country | US |
| Market Cap | 39.3B EUR |
| Operating Margin |
-33%
|
| Country | NL |
| Market Cap | 34.3B EUR |
| Operating Margin |
-22%
|
Biomarin Pharmaceutical Inc
Glance View
BioMarin Pharmaceutical Inc. is a leading biotechnology company that has carved out a niche in developing innovative therapies for rare genetic disorders. Founded in 1997 and headquartered in San Rafael, California, BioMarin has a mission driven by compassion and commitment to patient care. The company has made remarkable strides in advancing treatments for conditions that often lack effective medical options, such as Phenylketonuria (PKU) and mucopolysaccharidoses (MPS). With a robust pipeline of drugs, BioMarin's portfolio includes several approved therapies like Vimizim and Brineura, which are testament to their dedication to addressing unmet medical needs. With a focus on science and research, BioMarin aims to not only enhance quality of life for patients but also to ensure sustainable growth for its investors. As an investor, understanding BioMarin means recognizing its potential for long-term value based on innovation and market opportunities. The company is strategically positioned in a rapidly growing sector of personalized medicine, which is increasingly drawing attention as health systems embrace targeted treatments. BioMarin's commitment to R&D is evident in its ongoing clinical trials and collaborations with healthcare professionals and institutions, paving the way for future therapies and potentially transformative treatments. With the global rare disease market expanding, BioMarin stands at the forefront, ready to leverage its expertise and intellectual property to drive revenue growth. For investors, BioMarin represents not just a company with promising financials but also one with a profound impact on patient lives, making it an attractive proposition for those seeking both profit and purpose in their investments.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Biomarin Pharmaceutical Inc's most recent financial statements, the company has Operating Margin of 14.9%.
You don't have any saved screeners yet
